Cite
HARVARD Citation
Zhou, C. et al. (n.d.). Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): RATIONALE 303. Lung cancer. pp. S32-S33. [Online].